Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Oct 15;15(10):e0240467. doi: 10.1371/journal.pone.0240467

Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children

Juan C Lopez-Alvarenga 1,*,#, Geetha Chittoor 2,#, Solomon F D Paul 3,#, Sobha Puppala 4, Vidya S Farook 1, Sharon P Fowler 5, Roy G Resendez 1, Joselin Hernandez-Ruiz 6, Alvaro Diaz-Badillo 1, David Salazar 7, Doreen D Garza 7, Donna M Lehman 5, Srinivas Mummidi 1, Rector Arya 1, Christopher P Jenkinson 1, Jane L Lynch 8, Ralph A DeFronzo 5, John Blangero 1, Daniel E Hale 9, Ravindranath Duggirala 1
Editor: Fernando Guerrero-Romero10
PMCID: PMC7561152  PMID: 33057385

Abstract

Aim

Acanthosis nigricans (AN) is a strong correlate of obesity and is considered a marker of insulin resistance (IR). AN is associated with various other cardiometabolic risk factors (CMRFs). However, the direct causal relationship of IR with AN in obesity has been debated. Therefore, we aimed to examine the complex causal relationships among the troika of AN, obesity, and IR in Mexican Americans (MAs).

Methods

We used data from 670 non-diabetic MA children, aged 6–17 years (49% girls). AN (prevalence 33%) severity scores (range 0–5) were used as a quasi-quantitative trait (AN-q) for analysis. We used the program SOLAR for determining phenotypic, genetic, and environmental correlations between AN-q and CMRFs (e.g., BMI, HOMA-IR, lipids, blood pressure, hs-C-reactive protein (CRP), and Harvard physical fitness score (PFS)). The genetic and environmental correlations were subsequently used in mediation analysis (AMOS program). Model comparisons were made using goodness-of-fit indexes.

Results

Heritability of AN-q was 0.75 (p<0.0001). It was positively/significantly (p<0.05) correlated with traits such as BMI, HOMA-IR, and CRP, and negatively with HDL-C and PFS. Of the models tested, indirect mediation analysis of BMI→HOMA-IR→AN-q yielded lower goodness-of-fit than a partial mediation model where BMI explained the relationship with both HOMA-IR and AN-q simultaneously. Using complex models, BMI was associated with AN-q and IR mediating most of the CMRFs; but no relationship between IR and AN-q.

Conclusion

Our study suggests that obesity explains the association of IR with AN, but no causal relationship between IR and AN in Mexican American children.

1. Introduction

Acanthosis nigricans (AN) is an epidermal disorder of velvety thickening that primarily affects the axillae, posterior neck fold, flexor skin surfaces, and umbilicus [1,2]. AN has been associated with obesity and insulin resistance (IR) [1,2]; and, has been used as a marker for assessing type 2 diabetes (T2DM) risk in children [3]. For example, individuals with body mass index (BMI) greater than the 98th percentile were found to have a 62% prevalence of AN [4]; and, the presence of AN in Mexican individuals could predict IR with 66.7% sensitivity, which was shown to be influenced by the skin phototype [5]. Thus, AN has been used as a screening tool for identifying children at risk of insulin resistance (IR), T2DM, and cardiometabolic risk factors (CMRF) [2,68], in order to prevent progression of these disease conditions into adulthood.

There are remarkable ethnic disparities in the prevalence of AN. For example, in the United States (US), according to a cross-sectional study of young persons (the Research in Outpatient Settings Network), the prevalence of AN was found to be higher in Hispanics (19%) and American Indians (28%) compared to non-Hispanic whites (3%) [9]. As we reported previously, the occurrence of AN in Mexican Americans (MA) children and adolescents from families at high risk for obesity, CMRFs, and T2DM was 33% [10]. The diversity in clinical manifestations of AN can be attributed to the influences of genetic and environmental factors and their interactive influences on AN. Aside from these observations, it is not known whether AN and its clinical correlates, particularly obesity and IR, are causally related. Recently, Hudson et al. [11], using data from a community sample of adolescents with obesity, found that AN (or severity) was a poor marker of IR or cardiometabolic risk after adjusting for obesity (i.e., BMI).

Therefore, since the direct causal relationship of IR with AN in obesity is debatable, we aimed to assess genetic and environmental correlations between AN and CMRFs and examine the complex causal relationships among the troika of AN, obesity, and IR using data from children and adolescents from MA families. In contrast to population studies comprising of unrelated individuals, family-based studies such as ours provide opportunities not only to determine genetic basis of given traits, but also to assess phenotypic, genetic, and environmental correlations among correlated traits such as IR, AN, and obesity. Here, we analyzed the association of AN severity score with IR, obesity measures and other CMRFs. To assess the effects of IR and obesity on AN and other CMRFs, a mediation model was employed using information from the matrices of genetic and environmental correlations.

2. Materials and methods

This part of the study was made with unidentified data bases. Briefly, all research procedures were approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio. Written informed consent was obtained from one or both parents of each child. The San Antonio Family Assessment of Metabolic Risk Indicators in Youth (SAFARI) study, a community-based family study, was designed to identify signs of metabolic syndrome (MS) and future disease risk in MA children and adolescents in San Antonio, TX and surrounding areas, and to examine their genetic basis [10]. As part of the SAFARI study, 673 children and youth, aged 6–17 years old, were recruited from large, predominantly lower-income MA families at increased risk of obesity and T2DM. In specific, the SAFARI participants are the offspring of adults participated in three of our past or ongoing MA family studies: San Antonio Family Diabetes/Gallbladder Study (SAFDGS, n = 126), San Antonio Family Heart Study (SAFHS, n = 373) and, Veterans Administration Genetic Epidemiology Study (VAGES, n = 174), which were initiated in the early 1990s. However, based on a subset of the SAFARI children (~70%) for whom the information on birth places of mothers (and maternal grandparents) and fathers (and paternal grandparents) was available, some parents (i.e., mother or father) of the SAFARI children were born outside of the US, almost exclusively from Mexico as follows: Mothers = ~8% (grandmother = 19% and grandfather = 22%) and Fathers = ~12% (grandmother = 23% and grandfather = 26%). As reported previously [10], briefly, these 673 children generated 3,664 relative pairs including various types of relatives. Some examples are given as follows: Siblings = 383, 1st cousins = 550, 1st cousins once removed = 234, 2nd cousins = 661, 2nd cousins once removed = 512, 3rd cousins = 662, and 3rd cousins once removed = 137. Three of 673 children were found to have T2DM, based on our clinic examinations; these children were excluded from the analyses. Additional details on study and recruitment procedures were previously reported and discussed in Fowler et al. [10] This study considered data from a total of 670 non-diabetic SAFARI study participants (S1 Table).

2.1. Phenotypic and covariate data

An extensive battery of clinical tests and interviews was administered to SAFARI participants to collect information on medical history, family history, demographic, phenotypic, and environmental variables related to MS/CMRFs using standard protocols, as reported previously by Fowler et al. [10] The CMRFs considered for the current study included the following: body mass index [BMI: kg/m2], waist circumference (WC), fasting glucose (FG), fasting insulin (FI), homeostasis model assessment of insulin resistance (HOMA-IR; using information from FG and FI), high density lipoprotein cholesterol (HDL-C), triglycerides (TG), systolic (SBP) and diastolic (DBP) blood pressure, high-sensitivity C-reactive protein (CRP), and Harvard physical fitness score (PFS) [10].

In addition, the following phenotypic information described by Fowler et al. [10] was used for this study. BMI percentiles by sex and age were obtained from NHANES III to define obesity categories: normal = below the 85th percentile; overweight = ≥85th percentile and <95th percentile; and, obese = ≥95th percentile. Prediabetes was defined using information from impaired fasting glucose (IFG: Fasting plasma glucose (FPG) ≥ 100 and <126 mg/dl), impaired glucose tolerance (IGT: 2-h PG ≥ 140 and <200 mg/dl) or both, following the ADA guidelines [12]. Following our previous report, MS was defined as presence of ≥3 of the following 6 dichotomized MS component traits [10]: 1. Abdominal obesity: waist circumference ≥90th percentile for age, sex and MA ethnicity; 2. Hypertriglyceridemia: triglycerides ≥110 mg/dl and 3. Low HDL-C: ≤40 mg/dl; 4. Elevated blood pressure (SBP and/or DBP): ≥90th percentile for height, age and sex; 5. Glucose intolerance: IFG, IGT, or both as defined above; and 6. Hyperinsulinemia: >75th percentile for total SAFARI cohort (≥16.25 μIUml). Using a scale previously developed and validated by our group, presence/severity of AN on the neck was evaluated [13]. 16 AN severity score ranged from 0 to 5, and the dichotomous trait AN was defined as AN severity score ≥ 2. AN severity score was used as a quasi-quantitative trait for analysis and is referred to as AN-q. Pubertal status was assessed using Tanner staging.

2.2. Variance components analysis

The univariate and bivariate genetic analysis were conducted using the variance components approach (VCA) as implemented in the program SOLAR [14]. The heritability of AN-q was determined using the VCA. In a simple model, variances or covariances between relatives as a function of the genetic relationships can be specified, and the proportion of phenotypic variance that is attributed to (additive) genetic effects (i.e., heritability: h2) can be estimated from the components of variance [14,15]. 17 For such a model, the covariance matrix for a family (Ω) is given by: Ω = 2Φσ2g + Iσ2e, where Φ is the kinship matrix, σ2g is the genetic variance due to additive genetic effects, I is the identity matrix, and σ2e is the variance due to individual-specific environmental effects. A likelihood ratio test was used to test whether the heritability of AN-q was significant. Adjustment for covariate (e.g., age, sex, and pubertal status) influences were made in the analysis. Given the sample size (e.g., AN-q) and pedigree structure used for this study, we will have 80% power to detect heritabilities as small as 0.25. The phenotypic, genetic, and environmental correlations between two traits (e.g., AN-q and BMI) were determined using bivariate genetic analysis. This is an extension of the VCA where the phenotypic correlation (ρP) between a pair of quantitative traits (e.g., AN-q and BMI) can be partitioned into additive genetic (ρG) and environmental (ρE) components [15,16]. A likelihood ratio test was used to test whether a given correlation was significant. The additive genetic correlation (ρG) is a measure of the shared genetic basis of the two traits (i.e., pleiotropy), while the random environmental correlation (ρE) is a measure of the strength of the correlated response of a trait-pair to non-genetic factors. All analyses included adjustments for covariate (e.g., age, sex, and pubertal status) influences. Regarding power to detect genetic correlations in our data (e.g., AN-q and DBP trait pair), we will have 86% power for detecting a genetic correlation as small as 0.30. If non-normality of a given trait was an issue, we used appropriate transformations (i.e., log transformation or inverse normal transformation).

2.3. Mediation analysis

To assess causal relationships between traits, we used the mediation analysis [17]. In a simple model, a mediator (M) is a variable, which is in a causal sequence between an independent variable X and a dependent variable Y (i.e., X→M→Y). To begin with, for example, the structure considered BMI has effect on AN and IR, in turn IR affects AN and CMRFs. Using the genetic and environmental correlations (obtained after adjusting covariate effects such as age, sex and pubertal status) determined by bivariate genetic analysis, standardized beta coefficients were calculated to compare effects of loadings on clinical traits considered for this study. Models of full mediation, indirect mediation, and partial mediation were used for the given sets of data and tested using the goodness-of-fit statistics Akaike information criterion (AIC), and Bayes information criterion (BIC). The model selection between the competing models was made based on AIC and BIC criteria by making balance between goodness of fit and parsimony. The models with lower AIC and BIC were considered as the best models. All statistical analyses were performed using IBM® SPSS AMOS load 23. To assess power, the statistical analysis considered the effect of an independent variable (X) on a dependent variable (Y) through a mediating variable (M). The path diagram considered small effects for three parameters: α is the estimate of the effect of X on M; β is the estimate of the effect of M on Y adjusted for X, and the τ* parameter corresponds to the total effect of X on Y adjusted for M (and compared with τ without M adjustment). The smallest effect for a difference (τ−τ*) that we considered was 0.14 for each parameter; thus, the sample needed for 80% statistical power was 550 subjects [18].

3. Results

As stated above, of the 673 children, 3 of them with T2DM were excluded and only data from 670 nondiabetic children were used for the analyses. The 673 children represented 401 nuclear families (~2 children per nuclear family; range = 1–5 children) and generated 3,664 relative pairs [10]. The characteristics of the 670 nondiabetic children were reported previously by Fowler et al. [10] However, description of age, sex, pubertal status, overweight, obesity, prediabetes, MS, AN and AN-q measures pertaining to this study as outlined in Table 1. We found disturbingly high rates of overweight (19.1%), obesity (34%), pre-diabetes (13%), MS (19%), and AN (33%). The calculated heritability of AN severity score was 0.75 ± 0.11 (3.6 x 10−12).

Table 1. Characteristics of the 670 nondiabetic children and adolescents who participated in the SAFARI study, association between Acanthosis Nigricans (AN) and overweight, obese, prediabetes, and metabolic syndrome conditions, and heritability estimate for Acanthosis Nigricans severity scores (AN-q).

Variablea N Mean ± SD or % Acanthosis nigricans (AN)
% ORc 95% CIc P value
Girls 670 49.3 - - - -
Age (years) 670 11.5 ± 3.5 - - - -
BMI (kg/m2) 670 24.7 ± 6.5 - - - -
Normal weight 670 47.3 10.6 (33/278) 0.11 0.07–0.16 <0.001
Overweight 670 19.1 53.1 (186/164) 9.6 6.3–14.5 <0.001
Obese 670 33.6 65.3 (145/77) 9.3 6.4–13.5 <0.001
Prediabetes 630 13.2 47.0 (39/44) 1.9 1.2–3.0 0.008
Metabolic syndrome (MS) 625 18.7 67.0 (77/38) 5.7 3.7–8.8 <0.001
Acanthosis nigricans (AN) 661 33.1 - - - -
AN severity score (AN-q)d 660 1.3 ± 1.7 - - - -

aSee text for definitions, and the obesity/CMRFs used in the study were described previously by Fowler et al. 2013, and some were adapted from it for description in this table

badjusted for the age, sex, and pubertal-status effects

cOR = odds ratio and 95% CI = 95% Confidence Intervals. The ORs were calculated with a total of 661 children with complete data

dHeritability (h2) of AN-q = 0.75 (please see text.

The occurrence of AN increased by obesity status: normal weight (11%), overweight (53%), and obese (65%); by prediabetes status (47%); and by MS status (67%), respectively (Table 1). For example, based on odds ratios (ORs), children with AN are approximately 9/10 times more likely to be obese/overweight, 6 times more likely to have MS, and 2 times more likely to have prediabetes. Likewise, more or less similar patterns of relationships between AN-q and selected quantitative traits BMI, HOMA-IR, and CRP were observed (Fig 1). As expected, PFS was inversely associated with AN-q. As can be seen, AN-q exhibited linear trend with BMI, HOMA-IR, CRP and PFS (ANOVA for linear trend p < 0.001. Fig 1). As shown in Table 1, heritability (h2) estimate for AN-q was found to be significantly (P < 0.0001) and highly heritable (h2: 0.75). The results of phenotypic (ρP), genetic (ρG), and environmental (ρE), correlations between AN-q and obesity/CMRFs are given in Table 2. As can be seen, with an exception of FG, all of the phenotypic correlations were significant (ρP range: -0.35 [AN-q and PFS] to 0.66 [AN-q and WC]). Interestingly, excluding FG, the examined trait pairs exhibited significant correlations (ρG range: -0.57 [AN-q and PFS] to 0.79 [AN-q and WC]), while it is suggestive in nature between AN-q and HDL-C. None of the environmental correlations were significant. Most of these correlations were strongly attenuated when BMI was used as a covariate in the bivariate analyses, but not for HOMA-IR (S1 Fig). In our bivariate genetic analyses (Table 2), the assumption of complete pleiotropy between AN-q and a given CMRF was rejected for all traits (p -value range: 9 x10-9 to 0.001), in turn providing evidence for incomplete pleiotropy.

Fig 1.

Fig 1

Panel A. Positive association between BMI and AN-q. Panel B. HOMA-IR showed no difference between AN-q grade 0 vs. AN-q grade 1, but from AN-q grade 2 and so forth showed a positive relationship. Panel C. CRP showed no linear trend, but those with AN-q grade 3 and higher had elevated levels compared with lower scores. Panel D. PFS was inversely related with AN-q.

Table 2. Phenotypic (ρP), genetic (ρG), and environmental (ρE) correlations between Acanthosis Nigricans severity scores (AN-q) and obesity-related traits.

Trait ρP ρG ρE
PE SE p-Value PE SE p-Value PE SE p-Value
BMI (kg/m2)a 0.65 0.025 1 x 10−58 0.72 0.07 2 x 10−08 0.36 0.27 0.321
WC (mm) 0.66 0.020 9 x 10−63 0.79 0.07 1.1 x 10−07 0.45 0.17 0.101
SBP (mm Hg) 0.20 0.041 1.8 x 10−06 0.30 0.12 0.022 -0.04 0.25 0.886
DBP (mm Hg) 0.14 0.040 0.0011 0.30 0.13 0.026 -0.20 0.25 0.393
TG (mg/dl)a 0.31 0.039 9.8 x 10−13 0.41 0.11 0.0008 -0.09 0.35 0.822
HDL-C (mg/dl) -0.22 0.042 3.0 x 10−07 -0.25 0.13 0.064 -0.17 0.25 0.528
FG (mg/dl)a 0.02 0.043 0.6603 -0.02 0.17 0.923 0.07 0.19 0.717
FI (μIU/ml)a 0.31 0.039 2 x 10−13 0.46 0.13 0.0013 0.06 0.22 0.802
HOMA-IRb 0.31 0.039 2 x 10−13 0.40 0.12 0.003 0.14 0.23 0.591
CRP (ng/ml)b 0.26 0.042 3.5 x 10−09 0.38 0.16 0.032 0.17 0.19 0.412
PFSb -0.35 0.041 3.4 x 10−14 -0.57 0.13 0.0001 0.15 0.29 0.578

aTraits were log transformed for the genetic analyses

btraits were inverse normalized for the genetic analyses. All traits were adjusted for sex, age, and pubertal-status effects; BMI = body mass index; WC = waist circumference; SBP = systolic blood pressure; DBP = diastolic blood pressure; TG = triglycerides; HDL-C = high density lipoprotein cholesterol; FG = fasting plasma glucose; FI = fasting insulin; HOMA-IR = homeostasis model of assessment-insulin resistance; CRP = high-sensitivity C-reactive protein; PFS = Harvard physical fitness score.

In regard to the mediation analyses, overall, partial mediation models yielded substantially better indexes of goodness-of-fit compared with full mediation models. To start with, we examined the complex causal relationships among the troika of AN-q, HOMA-IR, and obesity (i.e., BMI) using information from genetic and environmental correlations (i.e., standardized beta coefficients). Of the models tested, as shown in Fig 2 panels A and B, a partial mediation model where BMI explained the relationship with both HOMA-IR and AN-q simultaneously had a better goodness-of-fit than the indirect mediation model that considered BMI with an effect on AN-q through HOMA-IR (BMI→HOMA-IR→AN-q). As can be seen in the partial mediation model, the effect of HOMA-IR was completely attenuated to explain AN-q. Since HOMA-IR showed non-significant effect on AN-q (HOMA-IR→AN-q), we opted not to consider this association further in evaluating other models. The partial mediation model was considered as the best model (AIC = 16.8 and BIC = 16.9) compared to the indirect mediation model (AIC = 261.3 and BIC = 261.4) since it was found to fit the data well.

Fig 2.

Fig 2

Panel A. Indirect mediation model shows BMI had an effect on AN-q through HOMA-IR. Panel B. Partial mediation model, the effect of HOMA-IR was completely attenuated to explain AN-q. This model fits the data well (The numbers correspond to environmental correlations and underlined numbers correspond to genetic correlations). Panel C and D are two models of partial mediation for BMI effects on metabolic and PFS traits. The thick arrows show standardized beta-coefficients greater than 0.3; thin lines show those beta coefficients between 0.3 and 0.1. Coefficients lower than 0.1 are not shown. The boxes indicate observed variables, circles indicate latent endogenous variables, those with a letter “e” are error terms. Panel C (genetic partial mediation) shows a web of genetic relationships. HOMA-IR and AN-q are mediators of BMI, perhaps activating other genes to have an effect on inflammation, lipids and physical fitness. Panel D (environmental partial mediation) supports the hypothesis that BMI is the main variable (with a small mediation effect of HOMA-IR on triglyceride concentrations) that influences the metabolic and PFS traits. This model had the best goodness-of-fit tests compared with other models of indirect effect of BMI by HOMA-IR or AN-q as mediators; * p-value < 0.01. BloodP: Blood pressure (latent factor). The dotted lines between AN-q and PFS show bidirectional (correlation) association between these two variables in an independent model.

As depicted in Fig 2 panels C and D, using complex models using information from genetic and environmental correlations (Table 2), BMI was associated with AN-q and HOMA-IR mediating most of the associations with CMRFs; but no relationship was found between HOMA-IR and AN-q. The complex associations of the three interrelated variables (HOMA-IR, BMI and AN-q) with other CMRFs (CRP, blood pressure, lipids and PFS) were analyzed by partial and indirect effects of BMI on CMRFs based on their genetic and environmental correlations (i.e., standardized beta coefficients). The models with partial mediation effects, based on genetic or environmental components, exhibited the best goodness-of-fitness indexes compared with the models with mediation effects (Genetic partial mediation vs. Genetic mediation: AIC and BIC = 10,380 vs. 15,105; and, Environmental partial mediation vs. Environmental mediation = 11,904 vs. 15,112). The two models of partial mediation (i.e., genetic [Panel C] and environmental [Panel D]) for BMI effects on metabolic and physical fitness traits are shown in Fig 2. The genetic mediation model (Fig 2 - Panel C) shows a web of BMI partial effects mediated by insulin resistance (HOMA-IR) and AN-q on CMRFs, in turn suggesting the potential activation of other genetic factors influencing inflammation, lipids and physical fitness. When the environmental correlations were analyzed, the model supports BMI as the main factor (with a small mediation effect of HOMA-IR on triglycerides) that influences the cardiometabolic and physical fitness traits.

4. Discussion

Acanthosis nigricans (AN) is a strong correlate of obesity and insulin resistance, and those affected with it are at higher risk of developing T2DM. Our data reveals that Mexican American children with AN are significantly, highly likely to be overweight/obese and to have metabolic syndrome or prediabetes. Almost all quantitative traits related to obesity and metabolic syndrome considered for this study are significantly associated with acanthosis nigricans (i.e., AN-q). Similar findings have been reported by other studies. For example, in a study of Latin-American children with obesity, the prevalence rates of AN, IR, metabolic syndrome were found to be 60.6%, 39.4%, and 36.1%, respectively. The prevalence of AN was found to be 70% in the insulin resistant group, while it was 54% in the insulin sensitive group [19]. Our study provides additional support to the statement that AN is highly heritable, and it is strongly associated with obesity-related risk factors, phenotypically and genetically [10]. However, since the direct causal relationship of insulin resistance (IR) with AN in obesity is debatable, this study determined genetic and environmental correlations between AN-q and CMRFs and examined the complex causal relationships among the troika of AN, obesity, and IR using data from children and adolescents from MA families.

To evaluate the potential causal relationships, a causation network approach was employed, which considered BMI effect on AN (i.e., AN-q) and IR as mediators associated with other CMRFs. Mediation analysis has been increasingly used in epidemiological [20] and genetic studies [21]. In our study, for example, BMI through IR was found to have remarkable environmental effects on lipid concentrations and physical fitness, based on a partial mediation model. The partial mediation model based on information from genetic effects exhibited a complex network of relationships between BMI, IR, AN, and other CMRFs. Interestingly, in contrast to some previous reports associated with malignancy and insulin receptor abnormalities, as described below, our findings failed to support the notion that IR causally explains benign AN; the partial mediation model where BMI explained both IR and AN had the best goodness of fit. This lack of direct effect between IR and AN is consistent with previous reports [22,23]. The mediation analysis also confirms that obesity (i.e., BMI) had partial effect, not only on IR and AN, but also on inflammation, blood pressure, lipids and physical fitness. Our findings are in line with a recent report that found the association of AN with hyperinsulinemia was attenuated after accounting for BMI influences in adolescents [11].

AN was initially observed association in malignancy [24] and later, Kahn and colleagues described extreme IR due to insulin receptor abnormalities (Type A IR) [25]. This excess insulin activates the insulin-like growth factor-1 receptors or fibroblast growth factor receptors, which has been implicated in the pathogenesis of AN [26]. 30 Interestingly, the initial classification of AN in subjects with obesity was defined as pseudoacanthosis, because its etiology and clinical manifestations were different from AN caused by insulin receptor mutations. However, subsequently, AN definition has been modified to include obesity, and the usage of pseudoacanthosis was discarded. Given the pandemic of obesity in global populations, the prevalence of AN has increased. In some recent studies, it was found to be quite high, ranging from 5% to 74% [2,27]. 31 Our study reiterates the notion that AN is strong correlate of obesity, and reveals the direct effect of obesity (i.e., BMI) than an indirect mediation through IR (i.e., HOMA-IR) on AN (i.e., AN-q). It is possible that the skin photo phenotype may have a modificatory effect on the IR and AN association [5]. Berstein et al. [28] found a lack of increase of pituitary peptides in obesity associated with AN, but this study included small sample size and the authors suggested further evaluations.

Insulin resistance and AN are partial mediators of BMI with genetic and environmental sharing influences on CRP, blood pressure, lipids, and physical fitness. The severity of AN is directly proportional to obesity, hyperinsulinemia, and metabolic syndrome-related risk factors which is also in line with the previous studies [2,8,2932]. Chronic inflammation associated with obesity explains the predominant effect of obesity relative to the other metabolic measures. In contrast, the IR as assessed by HOMA-IR, has minor influence on CRP concentrations in SAFARI children. The strong genetic correlation of AN with obesity measures (body composition and abdominal obesity) [33], was also paralleled by measures of insulin resistance and sensitivity [19] indicating that AN, obesity, and IR are strongly influenced by common genetic or pleiotropic influences in our study sample of Mexican American children. The pattern of correlations involving IR are similar to those reported in previous studies [10,3133]. In regard to CRP (a marker of inflammation), it is interesting to note that the transition between AN grade 2 and 3 appears to be a threshold for chronic inflammation. It is worthwhile to note that lypodistrophies, a group of diverse rare disorders, are associated with various disease conditions such as dyslipidemia, insulin resistance [34,35] and often with skeletal muscle abnormalities, like myoedema [36]. 40 It is also associated with AN via insulin resistance. The lypodistrophies have been described in Mexicans [37].

Aside from the debate that whether IR is a direct contributor to AN, it is evident from this study that AN is associated with a number of cardiometabolic risk factors through complex genetic and environmental relationships. Thus, AN is shown to be a compound marker of metabolic risk in children and adolescents. AN finding provides a simple non-invasive clinical tool that can be used for pediatric screening of cardiometabolic risks in the public health initiatives. It is currently implemented as the Texas Risk Assessment for Type 2 Diabetes in Children (TRAT2DC) program, a legislatively mandated program developed, coordinated, and administered by the University of Texas Rio Grande Valley Border Health Office. It assesses students across the schools in Texas to identify children at high risk of developing T2DM and alerts the parents of children who are found to be at risk of T2DM and other health conditions. During vision/hearing and scoliosis screenings of 1st, 3rd, 5th and 7th graders in public and private schools, certified individuals assess children for AN. Children who are identified with AN undergo additional assessments of BMI, BMI percentile, and blood pressure. As examples, here below we provide information from three independent school districts (ISDs) in the Rio Grande Valley area, where more than 90% of the population is Hispanic. During the 2017–2018 period, the prevalence of AN in Donna ISD was 13.9% (obesity = 80.0% and hypertension = 32.6%), and 5.7% (obesity = 93.7% and hypertension = 35.5%) in Mission ISD. The prevalence in Pharr-San Juan-Alamo ISD was 15.8% (obesity = 83.8% and hypertension = 32.0%).

In conclusion, obesity is shown to be a direct contributor to AN, hyperinsulinemia, and other CMRFs in Mexican American children. Moreover, AN is found to be a compound marker of complex cardiometabolic risk, which can be valuable, simple non-invasive clinical assessment tool for public health screening to assess cardiometabolic risk in children as exemplified by our TRAT2DC program. Early identification of AN in children should help to prevent or delay future health problems for children at risk of T2DM and its associated health conditions. Also, the findings form our mediation analyses mirror a complex interwork of relationships between obesity-related traits including AN, and IR and AN as partial mediators of BMI. There appears to be an immediate need for identifying the molecular mechanisms and pathways underlying these complex relationships among the Obesity/AN related phenotype examined in this study.

Supporting information

S1 Table. Detailed number of pairs classified by relationship.

(DOCX)

S1 Fig. Functions of selected metabolic traits by acanthosis nigricans score (ANc).

Panels A to D represent systolic blood pressure; E to H hsCRP; I to L triglycerides, and M to P PFS (Harvard test). The phenotypic function by ANc adjusted by sex, age and family is shown in the panels A, E, I and M. These functions shows clear positive or inverse relationship with ANc. The attenuation by BMI is shown in panels C, G, K and O; the hsCRP was maintained in a cubic polynomial and triglycerides on squared. The hsCRP shows a critical point between scores 2 to 3 showing a clear increase on the concentration; meanwhile triglycerides was positive for both BMI and ISI variables. When analyzed with the two covariates, all variables were attenuated.

(TIF)

S1 Data. RGen_corr_matrix.csv // Matrix of genetic correlations between traits.

(CSV)

S2 Data. REnv_corr_matrix.csv // Matrix of environmental correlations between traits.

(CSV)

S3 Data. Residuals.csv // Residuals after polygenic regression adjusted by sex, age and their interactions.

(CSV)

Acknowledgments

JCLA, GC, SFDP, and RD designed the research, conducted the research, analyzed the data, wrote the manuscript, and helped with the manuscript going through the peer-review process. SP, VSF, SPF, RA, and CPJ conducted the research, contributed to data analysis and provided critical review of the manuscript. RGR, ADB and JHR conducted the research and contributed to the manuscript preparation. DS, DDG, SM and JLL conducted research and reviewed/edited the manuscript. RAD, DML, JB, DEH and RD designed the research, provided study oversight, contributed to data analysis, and reviewed/edited the manuscript. All authors critically read, revised, and approved the final version of the manuscript before its submission. We thank Dr. William Rogers, Dr. Rolando Lozano, Richard Granato, Margaret Fragoso, David Rupert, Rhonda Lyons, Tanya Prado, Elizabeth Sosa, Bonnie Sanchez, Ram Prasad Upadhayay, and Nicolas Ballí for their excellent help and assistance. We thank the University Health System and the Texas Diabetes Institute for extending their clinical research facilities to the SAFARI study. Lastly and most importantly, we are deeply indebted to the children, teenagers, parents, and extended family members of the SAFARI study, whose great enthusiasm and commitment have made this research possible.

Data Availability

We provided supplementary files relating to the minimal data sets corresponding to the results including the matrices of genetic and environmental correlations and the data of residuals (i.e., residuals obtained for a given phenotype after adjusting for covariate effects) that we used for the analyses. None of them have any identification codes.

Funding Statement

This study was supported RD received grants: R01 HD049051/HD049051-5S1 [ARRA], HD041111, DK053889, DK042273, DK047482, MH059490, P01 HL045522, K01 DK064867, M01-RR- 01346, and Veterans Administration Epidemiologic Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Some of the investigators received salaries from some of the grants as follows: R01 HD049051/HD049051-5S1 [ARRA] (RD, DEH, JB, RAD, CPJ, RA, SP, VSF, SPF, RGR), HD041111 (RD, JB, RAD, CPJ, RA, RGR), DK053889 (RD, JB, CPJ, SP, VSF, SPF, RGR), DK042273 (DML, RD, JB), DK047482 (DML), MH059490 (JB), P01 HL045522 (JB, RD), and Veterans Administration Epidemiologic Grant (RAD, CPJ). The AT&T Genomics Computing Center supercomputing facilities used for this work were supported in part by a gift from the AT&T Foundation and with support from the National Center for Research Resources Grant Number S10 RR029392. This investigation was conducted in facilities constructed with support from Research Facilities Improvement Program grants C06 RR013556 and C06 RR017515 from the National Center for Research Resources of the National Institutes of Health.

References

  • 1.Abraham C, Rozmus C. Is acanthosis nigricans a reliable indicator of type 2 diabetes in obese childen and adolescents? The Journal of Shool Nursing 2012; 28: 195–205. [DOI] [PubMed] [Google Scholar]
  • 2.Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007;57: 502–508. 10.1016/j.jaad.2006.08.016 [DOI] [PubMed] [Google Scholar]
  • 3.American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23 (3): 381–389. 10.2337/diacare.23.3.381 [DOI] [PubMed] [Google Scholar]
  • 4.Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR; Cherokee Diabetes Study. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care 2002;25: 1009–1014. 10.2337/diacare.25.6.1009 [DOI] [PubMed] [Google Scholar]
  • 5.Lopez-Alvarenga JC, García-Hidalgo L, Landa-Anell MV, Santos-Gomez R, González-Barranco J, Comuzzie A. Influence of skin color on the diagnostic utility of clinical acanthosis nigricans to predict insulin resistance in obese patients. Archives of Medical Research 2006; 37: 744–748. 10.1016/j.arcmed.2005.12.007 [DOI] [PubMed] [Google Scholar]
  • 6.Kluczynik CE, Mariz LS, Souza LC, Solano GB, Albuquerque FC, Medeiros CC. Acanthosis nigricans and insulin resistance in overweight children and adolescents. An Bras Dermatol 2012;87: 531–537. 10.1590/s0365-05962012000400002 [DOI] [PubMed] [Google Scholar]
  • 7.Valdés Rodríguez R, Moncada González B, Rivera Rodríguez SP, Aradillas García C, Hernández-Rodríguez H, Torres Álvarez B. Skin tags and Acanthosis nigricans: association with insulin resistance and overweight in Mexican children. Gac Med Mex 2011;147: 297–302. [PubMed] [Google Scholar]
  • 8.Plascencia Gómez A, Vega Memije ME, Torres Tamayo M, Rodríguez Carreón AA. Skin Disorders in Overweight and Obese Patients and Their Relationship With Insulin. Actas Dermosifiliogr 2013; e-pub ahead of print 12 November 2013; 10.1016/j.ad.2013.09.008 [DOI] [PubMed] [Google Scholar]
  • 9.Kong AS, Williams RL, Smith M, Sussman AL, Skipper B, Hsi AC et al. ; RIOS Net Clinicians. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med 2007;5: 202–208. 10.1370/afm.678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fowler SP, Puppala S, Arya R, Chittoor G, et al. Genetic epidemiology of cardiometabolic risk factors and their clustering patterns in Mexican American children and adolescents: the SAFARI Study. Hum Genet 2013;132: 1059–1071. 10.1007/s00439-013-1315-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hudson LD, Kinra S, Wong ICK, Viner RM. Arterial stiffening, insulin resistance and acanthosis nigricans in a community sample of adolescents with obesity. International Journal of Obesity 2017; 41: 1454–1456. 10.1038/ijo.2017.105 [DOI] [PubMed] [Google Scholar]
  • 12.American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes 2020. Diabetes Care 2020; 43 (suppl 1): S14–S31. 10.2337/dc20-S002 [DOI] [PubMed] [Google Scholar]
  • 13.Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care 1999; 22: 1655–1659. 10.2337/diacare.22.10.1655 [DOI] [PubMed] [Google Scholar]
  • 14.Hopper JL, Matthews JD. Extensions to multivariate normal models for pedigree analysis. Ann Hum Genet 1982; 46:373–383. 10.1111/j.1469-1809.1982.tb01588.x [DOI] [PubMed] [Google Scholar]
  • 15.Falconer DS, Mackay TFC. Variance. In: Introduction to Quantitative Genetics. 4th edition. Longman Ed. London. 1996: 122–144.
  • 16.Lange K, Boehnke M. Extensions to pedigree analysis. IV. Covariance components models for multivariate traits. Am J Med Genet. 1983. March;14(3):513–24. 10.1002/ajmg.1320140315 [DOI] [PubMed] [Google Scholar]
  • 17.MacKinnon D, Fairchild AJ, Fritz M. Mediation analysis. Annu Rev Psychol 2007; 58: 593 10.1146/annurev.psych.58.110405.085542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Fritz M, MacKinnon. Required sample size to detect mediated effect. Pshychol Sci 2007; 18: 233–239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatrics 2008; 8:31 10.1186/1471-2431-8-31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Liu S-h, Ulbricht CM, Chrysanthopoulou SA, Lapane KL. Implementation and reporting of causal mediation analysis in 2015: a systematic review in epidemiological studies. BMC Res Notes 2016; 9: 354 10.1186/s13104-016-2163-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lutz S, Hokanson JE. Mediation analysis in genome-wide association studies: current perspectives. Open Access Bioinformatics 2015; 7: 1–5. [Google Scholar]
  • 22.Hudson LD, Kinra S, Wong ICK, Viner RM. Arterial stiffening, insulin resistance and acanthosis nigricans in a community sample of adolescents with obesity. Intern J Obes 2017; 41: 1454–1456. [DOI] [PubMed] [Google Scholar]
  • 23.Kong AS, Vanderbloemen L, Skipper B, et al. Acanthosis nigricans predicts the clustering of metabolic syndrome components in Hispanic elementary school-aged children. J Pediatr Endocrinol Metab 2012;25: 1095–1102. 10.1515/jpem-2012-0117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sneddom IB. Roberts JB. An incomplete form of acanthosis nigricans. Gut. 1962. September; 3(3): 269–272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976;294: 739–745. 10.1056/NEJM197604012941401 [DOI] [PubMed] [Google Scholar]
  • 26.Cruz PDJ, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98: 82–5S. [DOI] [PubMed] [Google Scholar]
  • 27.Burke JP, Duggirala R, Hale DE, Blangero J, Stern MP. Genetic basis of acanthosis nigricans in Mexican Americans and its association with phenotypes related to type 2 diabetes. Hum Genet 2000;106: 467–472. 10.1007/s004390000274 [DOI] [PubMed] [Google Scholar]
  • 28.Berstein JE, Rothstein J, Soltani K, Levine L. Neuropeptides in the pathogenesis of obesity-associated benign acanthosis nigricans. The Journal of Investigative Dermatology 1983; 80: 7–9. 10.1111/1523-1747.ep12530848 [DOI] [PubMed] [Google Scholar]
  • 29.Kobaissi HA, Weigensberg MJ, Ball GD, Cruz ML, Shaibi GQ, Goran MI. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care 2004;27: 1412–1416. 10.2337/diacare.27.6.1412 [DOI] [PubMed] [Google Scholar]
  • 30.Kong AS, Williams RL, Rhyne R, et al. PRIME Net Clinicians. Acanthosis Nigricans: high prevalence and association with diabetes in a practice-based research network consortium—a PRImary care Multi-Ethnic network (PRIME Net) study. J Am Board Fam Med 2010;23: 476–485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Garofalo L, Biscozzi AM, Mastrandrea V, Bonifazi E. Acanthosis nigricans vulgaris. A marker of hyperinsulinemia. Eur J Pediat Dermatol 2003;13: 85–88. [Google Scholar]
  • 32.Copeland K, Pankratz K, Cathey V, et al. Acanthosis Nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children. J Okla State Med Assoc 2006;99: 19–24. [PubMed] [Google Scholar]
  • 33.Brickman WJ, Huang J, Silverman BL, Metzger BE. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 2010;156: 87–92. 10.1016/j.jpeds.2009.07.011 [DOI] [PubMed] [Google Scholar]
  • 34.Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350: 1220–1234. 10.1056/NEJMra025261 [DOI] [PubMed] [Google Scholar]
  • 35.Garg A, Agarwal AK. Lipodystrophies: Disorders of adipose tissue biology. Biochim Biophys Acta 2009: 1791: 507–513. 10.1016/j.bbalip.2008.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ghanem Q. Percussion myoedema in a Pakistani boy with Berardinelly Seip lipodystrophy syndrome. Clin Genet 1993: 44: 277–278. 10.1111/j.1399-0004.1993.tb03899.x [DOI] [PubMed] [Google Scholar]
  • 37.Simha V, Agarwal AK, Aronin PA, Iannaccone ST, Garg A. Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. Am J Med Genet A 2008; 146A(18): 2318–2326. 10.1002/ajmg.a.32457 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Fernando Guerrero-Romero

8 Jun 2020

PONE-D-20-02036

Acanthosis Nigricans as a Composite Marker of Cardiometabolic Risk and Its Complex Association with Obesity and Insulin Resistance in Mexican American Children

PLOS ONE

Dear Dr. Juan Carlos Lopez-Alvarenga,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewer(s) have suggested some revisions to your manuscript. Therefore, I invite you to respond to the reviewer(s)' comments and revise your manuscript.

Please submit your revised manuscript by Jul 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Fernando Guerrero-Romero, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

'..This study was supported by grants from the National Institutes of Health (R01 HD049051, HD041111, DK053889, DK042273, K01DK064867, P01 HL045522, DK047482, MH059490, M01-RR-01346, and HD049051-5S1 [ARRA]). This work was also supported by a Veterans Administration Epidemiologic grant to R.A.D...  The AT&T Genomics Computing Center supercomputing facilities used for this work were supported in part by a gift from the AT&T Foundation and with support from the National Center for Research Resources Grant Number S10 RR029392. This investigation was conducted in facilities constructed with support from Research Facilities Improvement Program grants C06 RR013556 and C06 RR017515 from the National Center for Research Resources of the National Institutes of Health...'

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

'RD received grants: R01 HD049051, HD041111, DK053889, DK042273, K01DK064867, P01 HL045522, DK047482, MH059490, M01-RR-01346, and HD049051-5S1 [ARRA]'

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript describes the relationship between obesity, insulin resistance (IR), and acanthosis nigricans (AN). The relationship among these factors is not novel, but the authors have a novel statistical approach using many variables, genetics, and phenotypic. They found that obesity explains the association of IR with AN, but no causal relationship between IR and AN in Mexican American children. The results of this study could be important in clinical practice due to the AN severity-classification, which is low-cost, and it seems to be easy to measure, is correlated with cardiometabolic factors. However, the manuscript has critical methodological issues that need clarification and to be revised.

Main Concerns

1. The kinship of the sample is not describing in the manuscript; I mean the pairs of full or half-brothers, cousins, etc. It is not clear which kind of parentage was used for hereditability estimation; in other words, it is not clear which kinship measures fed the model. It is also not clear if hereditability is the only genetic variable used in the study.

2. Describe criteria cut-off for prediabetes and cardiometabolic factors; cut-of for dichotomized IFG, IGT, HDL-C, blood pressure and son on.

3. Which were the environmental variables used? Those need clarification.

4. The authors mention three methods to choose the best model (goodness-of-fit statistics, Akaike information criterion, and Bayes information). Still, they did not specify the threshold criterion to select the models. For example, mention the difference in the AIC values. This is a concerning matter for the reproducibility and the credibility of the chosen best model.

5. Mediation analysis has enough statistical power, but what about with the variance components analysis?

6. For clinical practice, are the pediatricians familiarized with the AN severity scale used in this study? If they are not, extending the AN as a proxy of cardiometabolic factors could be a limitation.

Reviewer #2: Please add a brief discussion on the ethnicity of the experimental group, in addition to describing them as Mexican Americans please provide more information on the ethnic ancestry of their two previous generations. It is also relevant to know if they were born in the US, if they are US citizens, or if they were born in Mexico and migrated to the US. This would provide a better understanding on the possible applications of the reported results to Mexican children living in urban areas similar to the state of Texas, such as the nearby city of Monterrey, Nuevo Leon, Mexico.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Julio Granados

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Fernando Guerrero-Romero

28 Sep 2020

Acanthosis Nigricans as a Composite Marker of Cardiometabolic Risk and Its Complex Association with Obesity and Insulin Resistance in Mexican American Children

PONE-D-20-02036R1

Dear Dr. Lopez-Alvarenga,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Fernando Guerrero-Romero, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Fernando Guerrero-Romero

2 Oct 2020

PONE-D-20-02036R1

Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children

Dear Dr. Lopez-Alvarenga:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Fernando Guerrero-Romero

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Detailed number of pairs classified by relationship.

    (DOCX)

    S1 Fig. Functions of selected metabolic traits by acanthosis nigricans score (ANc).

    Panels A to D represent systolic blood pressure; E to H hsCRP; I to L triglycerides, and M to P PFS (Harvard test). The phenotypic function by ANc adjusted by sex, age and family is shown in the panels A, E, I and M. These functions shows clear positive or inverse relationship with ANc. The attenuation by BMI is shown in panels C, G, K and O; the hsCRP was maintained in a cubic polynomial and triglycerides on squared. The hsCRP shows a critical point between scores 2 to 3 showing a clear increase on the concentration; meanwhile triglycerides was positive for both BMI and ISI variables. When analyzed with the two covariates, all variables were attenuated.

    (TIF)

    S1 Data. RGen_corr_matrix.csv // Matrix of genetic correlations between traits.

    (CSV)

    S2 Data. REnv_corr_matrix.csv // Matrix of environmental correlations between traits.

    (CSV)

    S3 Data. Residuals.csv // Residuals after polygenic regression adjusted by sex, age and their interactions.

    (CSV)

    Attachment

    Submitted filename: Response to Reviewers 20Aug20.pdf

    Data Availability Statement

    We provided supplementary files relating to the minimal data sets corresponding to the results including the matrices of genetic and environmental correlations and the data of residuals (i.e., residuals obtained for a given phenotype after adjusting for covariate effects) that we used for the analyses. None of them have any identification codes.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES